Resignation of Non-Executive Director, Executive Director and Independent Non-Executive Director.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.2 pts more than Nifty Microcap 250 and 1.6 pts more than its Pharmaceuticals & Biotechnology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The company announced sweeping board changes on January 19, 2026, all stemming from a change in management/control through an open offer. Four directors resigned: Whole Time Director Balakrishna Koppula, Non-Executive Director Vanitha Nagulavari, and two Independent Directors (Prasada Rao Kalluri and Mohammed Baba). CFO CHDVV Prasad Rao also stepped down the same day. In their place, five new directors were appointed, including Poonam Chaturvedi as Managing Director, Mr. Padmanaban Krishnamoorthy as Non-Executive Director and Chairperson, V. Varalakshmi as Non-Executive Director, and Ashok Chhaganbhai Patel and Ritika Agrawal as Independent Directors for 5-year terms. Ravindranath Rajaram was appointed as the new CFO. The Audit Committee, Nomination & Remuneration Committee, and Stakeholder Relationship Committee were fully reconstituted. The board also approved a name change to CCME Global Limited (or CCME International/Worldwide Limited), subject to MCA and shareholder approval.
This is a complete takeover-style management change — virtually the entire board and the CFO have been replaced by a new controlling group's nominees. Shareholders should expect a shift in business direction under the new management, and the proposed rename to CCME Global signals a potential rebranding tied to the new owner's identity.